Noninvasive Antenatal Screening for Fetal RHD in RhD Negative Women to Guide Targeted Anti-D Prophylaxis

Frederik Banch Clausen; Klaus Rieneck; Grethe Risum Krog; Birgitte Suhr Bundgaard; Morten Hanefeld Dziegiel

doi:10.1007/978-1-4939-8889-1_23

Noninvasive Antenatal Screening for Fetal RHD in RhD Negative Women to Guide Targeted Anti-D Prophylaxis

Frederik Banch Clausen, Klaus Rieneck, Grethe Risum Krog, Birgitte Suhr Bundgaard, Morten Hanefeld Dziegiel

Department of Clinical Immunology

14 Citations (Scopus)

Abstract

RhD negative pregnant women who carry an RhD positive fetus are at risk of immunization against the D antigen, which may result in hemolytic disease of the fetus and the newborn. Predicting the fetal RhD status by noninvasive antenatal screening for the fetal RhD gene (RHD) can guide targeted use of antenatal anti-D prophylaxis.Cell-free fetal DNA is extracted from maternal plasma from RhD negative pregnant women at a gestational age of 25 weeks. A real-time PCR-based detection of two RHD exons enables reliable prediction of the fetal RhD status to determine the administration of antenatal prophylaxis, as well as postnatal prophylaxis.

Original language	English
Journal	Methods in molecular biology
Volume	1885
Pages (from-to)	347-359
Number of pages	13
ISSN	1064-3745
DOIs	https://doi.org/10.1007/978-1-4939-8889-1_23
Publication status	Published - 2019

Keywords

Anemia, Hemolytic/etiology
Blood Grouping and Crossmatching/methods
Female
Humans
Pregnancy
Prenatal Diagnosis/methods
Real-Time Polymerase Chain Reaction
Rh-Hr Blood-Group System/genetics
Rho(D) Immune Globulin/genetics
Noninvasive RHD typing
Hemolytic disease of the fetus and newborn
Antenatal prophylaxis
Real-time PCR
Anti-D
Cell-free fetal DNA

Access to Document

10.1007/978-1-4939-8889-1_23

Cite this

@article{78a964005ece40459a996f33adbe0b49,

title = "Noninvasive Antenatal Screening for Fetal RHD in RhD Negative Women to Guide Targeted Anti-D Prophylaxis",

abstract = "RhD negative pregnant women who carry an RhD positive fetus are at risk of immunization against the D antigen, which may result in hemolytic disease of the fetus and the newborn. Predicting the fetal RhD status by noninvasive antenatal screening for the fetal RhD gene (RHD) can guide targeted use of antenatal anti-D prophylaxis.Cell-free fetal DNA is extracted from maternal plasma from RhD negative pregnant women at a gestational age of 25 weeks. A real-time PCR-based detection of two RHD exons enables reliable prediction of the fetal RhD status to determine the administration of antenatal prophylaxis, as well as postnatal prophylaxis.",

keywords = "Anemia, Hemolytic/etiology, Blood Grouping and Crossmatching/methods, Female, Humans, Pregnancy, Prenatal Diagnosis/methods, Real-Time Polymerase Chain Reaction, Rh-Hr Blood-Group System/genetics, Rho(D) Immune Globulin/genetics, Noninvasive RHD typing, Hemolytic disease of the fetus and newborn, Antenatal prophylaxis, Real-time PCR, Anti-D, Cell-free fetal DNA",

author = "Clausen, {Frederik Banch} and Klaus Rieneck and Krog, {Grethe Risum} and Bundgaard, {Birgitte Suhr} and Dziegiel, {Morten Hanefeld}",

year = "2019",

doi = "10.1007/978-1-4939-8889-1_23",

language = "English",

volume = "1885",

pages = "347--359",

journal = "Methods in molecular biology",

issn = "1064-3745",

publisher = "Humana Press, Inc",

}

TY - JOUR

T1 - Noninvasive Antenatal Screening for Fetal RHD in RhD Negative Women to Guide Targeted Anti-D Prophylaxis

AU - Clausen, Frederik Banch

AU - Rieneck, Klaus

AU - Krog, Grethe Risum

AU - Bundgaard, Birgitte Suhr

AU - Dziegiel, Morten Hanefeld

PY - 2019

Y1 - 2019

N2 - RhD negative pregnant women who carry an RhD positive fetus are at risk of immunization against the D antigen, which may result in hemolytic disease of the fetus and the newborn. Predicting the fetal RhD status by noninvasive antenatal screening for the fetal RhD gene (RHD) can guide targeted use of antenatal anti-D prophylaxis.Cell-free fetal DNA is extracted from maternal plasma from RhD negative pregnant women at a gestational age of 25 weeks. A real-time PCR-based detection of two RHD exons enables reliable prediction of the fetal RhD status to determine the administration of antenatal prophylaxis, as well as postnatal prophylaxis.

AB - RhD negative pregnant women who carry an RhD positive fetus are at risk of immunization against the D antigen, which may result in hemolytic disease of the fetus and the newborn. Predicting the fetal RhD status by noninvasive antenatal screening for the fetal RhD gene (RHD) can guide targeted use of antenatal anti-D prophylaxis.Cell-free fetal DNA is extracted from maternal plasma from RhD negative pregnant women at a gestational age of 25 weeks. A real-time PCR-based detection of two RHD exons enables reliable prediction of the fetal RhD status to determine the administration of antenatal prophylaxis, as well as postnatal prophylaxis.

KW - Anemia, Hemolytic/etiology

KW - Blood Grouping and Crossmatching/methods

KW - Female

KW - Humans

KW - Pregnancy

KW - Prenatal Diagnosis/methods

KW - Real-Time Polymerase Chain Reaction

KW - Rh-Hr Blood-Group System/genetics

KW - Rho(D) Immune Globulin/genetics

KW - Noninvasive RHD typing

KW - Hemolytic disease of the fetus and newborn

KW - Antenatal prophylaxis

KW - Real-time PCR

KW - Anti-D

KW - Cell-free fetal DNA

UR - http://www.scopus.com/inward/record.url?scp=85058170091&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-8889-1_23

DO - 10.1007/978-1-4939-8889-1_23

M3 - Journal article

C2 - 30506209

SN - 1064-3745

VL - 1885

SP - 347

EP - 359

JO - Methods in molecular biology

JF - Methods in molecular biology

ER -

Noninvasive Antenatal Screening for Fetal RHD in RhD Negative Women to Guide Targeted Anti-D Prophylaxis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this